ECM-degrading enzymes [3]. This increased proteolytic activity is presumably required for degradation of the normal ECM by infiltrating inflammatory and fibroblasThe hallmark of terminal renal failure is the irreverstic cells and its replacement by abnormal ECM. Two ible destruction of the normal renal parenchyma, more main degrading systems are known to play a role: the or less rapidly invaded and replaced by fibrosis. To date, matrix metalloproteinases (MMPs) and the plasminogen although numerous studies have been reported on the activation system (PAS) [4]. The relationship between various factors that may promote, or conversely delay, the these systems is numerous and has been reviewed elseprogression of chronic renal failure, we are still looking for where recently [5][6][7]. The aim of the present review is an integrated and unifying understanding of the molecular to analyze the available experimental and clinical data and cellular mechanisms implicated in the renal fibrosupporting a role for the main inhibitor of plasminogen genic process. Fibrosis is due to the abnormal accumulaactivation, the plasminogen activator inhibitor type 1 (PAI-1), as a key player in renal fibrogenesis.
ECM-degrading enzymes [3] . This increased proteolytic activity is presumably required for degradation of the normal ECM by infiltrating inflammatory and fibroblasThe hallmark of terminal renal failure is the irreverstic cells and its replacement by abnormal ECM. Two ible destruction of the normal renal parenchyma, more main degrading systems are known to play a role: the or less rapidly invaded and replaced by fibrosis. To date, matrix metalloproteinases (MMPs) and the plasminogen although numerous studies have been reported on the activation system (PAS) [4] . The relationship between various factors that may promote, or conversely delay, the these systems is numerous and has been reviewed elseprogression of chronic renal failure, we are still looking for where recently [5] [6] [7] . The aim of the present review is an integrated and unifying understanding of the molecular to analyze the available experimental and clinical data and cellular mechanisms implicated in the renal fibrosupporting a role for the main inhibitor of plasminogen genic process. Fibrosis is due to the abnormal accumulaactivation, the plasminogen activator inhibitor type 1 (PAI-1), as a key player in renal fibrogenesis.
The plasminogen/plasmin system was first recognized for its fibrin-degrading activity and is the main, if not the only, efficient fibrinolytic system in vivo (Fig. 1) .
of the active site zink atom to an unpaired cystein of the propeptide domain. Disruption of the cystein-zink bound The limiting rate of plasmin generation is the amount of tissue-type (t-PA) or urokinase-type (u-PA) plasminby conformational change or by limited proteolysis, as produced by plasmin, leads to the opening of the switch. ogen activators (PAs) in their active forms [4] . This amount is tightly regulated through the control of the Then the autocatalytic cleavage of the propeptide yields the active enzyme [7] . The activation of MMPs may also synthesis and release of the proenzyme forms of PA, the extracellular activation of these proenzymes, and their occur through the cleavage by membrane-bound MMPs, which are called MT-MMPs. The activation of MMP2 inhibition by specific inhibitors such as PAI-1, PAI-2, and PAI-3 [5] . These inhibitors belong to the SERPIN at the cell surface is due to MT1-MMP, which binds TIMP-2 and forms a ternary complex with MMP2. Active family, after the SERine Protease INhibitor. PAI-1, a 50 kD glycoprotein, is the main PAI secreted in vivo MMP2 is then released into the extracellular space, but may also remain at the cell surface, where it has been and is a potent fast-acting and irreversible inhibitor of t-PA and u-PA but not of plasmin. It forms stochiometric shown to bind to the integrin ␣ v ␤ 3 [9] . Interestingly, in our laboratory, u-PA was shown to promote MMP2 acticomplexes with active PAs, which are subsequently endocytozed and degraded. Membrane receptors for u-PA vation when purified u-PA was added to the culture medium conditioned by human mesangial cells, but not and t-PA have been identified that facilitate the activation of plasminogen at the cell surface and the activation when added to purified pro-MMP2. We were able to demonstrate that mesangial cells release a soluble form of the PA proenzymes by trace amounts of plasmin [8] . In addition, u-PA receptor (u-PAR) plays a role in bindof MT1-MMP that was activated by u-PA and then was responsible for MMP2 activation [10] . PAI-1, as a potent ing and internalization of u-PA/PAI complexes and in cell adhesion and migration through an interaction with inhibitor of u-PA, inhibits u-PA-induced, MT1-MMPmediated MMP2 activation [11] . Thus, PAI-1 regulates vitronectin and integrins [8] .
The other main extracellular proteolytic system, the plasmin formation and fibrinolysis and, through several different mechanisms, plays a role in the control of MMP MMPs and their inhibitors (TIMP-1, TIMP-2, and TIMP-3), exist in a number of different metalloproteinactivation. Its role in matrix remodeling derives from these effects. Moreover, PAI-1 is also a component of ases that contain several conserved motifs and a zinc binding site, which is required for full enzymatic activity.
the ECM, where it seems to bind tightly to the somatomedin B domain of vitronectin [12] . This interaction To date, at least 20 MMPs have been identified that belong to four different groups according to their specistabilizes PAI-1 in an active conformation, still able to inhibit extracellular PA activity, and thus plasmin formaficity: (1) the collagenases, which cleave preferentially interstitial collagens type I and III; (2) the gelatinases, tion and MMP activation. In addition, PAI-1 binding to vitronectin has been shown to disrupt the interaction which degrade the collagens type IV and V; (3) the stromelysins, which degrade gelatin, fibronectin, laminin, between uPAR and vitronectin, preventing adhesion of the cell to the ECM. uPAR may bind u-PA and promote and elastin; and (4) the membrane-type MMPs (MTMMPs) [7] . The MMPs are secreted in the extracellular ECM degradation either directly by u-PA through the proteolytic cleavage of fibronectin, laminin, and other space in catalytically latent forms because of the binding Renal expression of PAI-1 total PAI-1, a latent inactive form, and a form complexed to t-PA. The plasma level of circulating PAI-1 has been Plasminogen activator inhibitor type 1 expression is almost undetectable in the normal mouse, rat, and hushown to be genetically controlled, and a polymorphism in the 5Ј gene promoter has been described. Two alleles, man kidney by immunohistochemistry and in situ hybridization [28, 29, 42] . Conversely, it has been shown that 4G and 5G, at position Ϫ674 in the promoter region, are encountered, and the plasma level of PAI-1 has been t-PA is expressed by endothelial cells in the kidney and by epithelial cells of the inner medulla collecting duct, shown to be higher in patients with the 4G/4G genotype than in those with the 5G/5G genotype, while the heterowhile u-PA synthesis has been localized in epithelial cells of the proximal tubule, especially in the S3 segment, and zygotes 4G/5G have intermediate values [40] . The genotype determines not only the plasma level of PAI-1, but in the large ascending limb of the Henle's loop. More recently, the binding of u-PA at the apical membrane of it has been shown also to be associated with an increased risk of myocardial infarction in adult male patients. The epithelial cells of the collecting duct has been observed. Interestingly, MMP9 binding was also demonstrated at molecular mechanisms involved in the increased synthe-␣ actin, whereas they do produce it in large amounts when they are seeded in two-dimensional culture on plastic. We have shown that PAI-1 produced by mesangial cells in culture is released in the culture medium or incorporated in the ECM, as demonstrated by immunocytochemistry and in situ hybridization (Fig. 4) [45, 46] . Similarly, cultured mesangial cells express smooth muscle cell ␣ actin, and both PAI-1 and ␣ actin have been recognized as in vivo and in vitro markers of mesangial cell activation [47] . In contrast, when mesangial cells are embedded in three-dimensional matrix or when they formed hillocks, they ceased proliferating to express smooth muscle specific ␣ actin and to synthesize PAI-1. This suggests that in the normal kidney, a tonic inhibition sulfate proteoglycans may be responsible for such an inhibition since we demonstrated that heparin and nonanticoagulant heparan sulfate derivatives were able to inhibit PAI-1 accumulation in the matrix of cultured the same place, suggesting a role and perhaps an interachuman mesangial cells [48] . In diseased conditions in tion of luminal proteinases in the collecting duct funcvivo, human mesangial cells express PAI-1, and this uptions [43] . Such a role for luminal proteinases has been regulation may be related to the stimulation by various recently described for the regulation of the epithelial cytokines or growth factors, such as TNF-␣ or IL-1␤ sodium channel activity [44] .
[21], TGF-␤, and thrombin [49] . On the other hand, the Several studies have shown that PAI-1 synthesis and up-regulation of PAI-1 synthesis in vivo may result from deposition are promoted in the kidney during experithe abolition of the tonic inhibition of PAI-1 gene tranmental and human nephropathies (Table 1) . PAI-1 deposcription by the surrounding normal mesangial matrix. sition may occur along with an inflammatory reaction Actually, integrin-mediated ECM interactions with variassociated with an activation of coagulation and fibrin ous cell types have been shown to regulate gene expresdeposition in the intravascular or the extravascular spaces sion. The signaling pathways involve intracellular integ- [42, 30] . In thrombotic microangiopathy [25, 28] , which rin-associated proteins such paxillin, ␤ catenin, vinculin, characterized the pathological pattern of hemolytic ureand talin, which then recruit cytoskeleton proteins and mic syndrome, and in inflammatory glomerulonephritis mitogen-activated protein kinases. In vitro, these pathwith extracapillary crescent formation [25-27, 29], we ways have been shown to stimulate PAI-1 gene transcripand others were able to demonstrate the presence of tion strongly [50] . However, in vivo, less is known about PAI-1 antigen by immunohistochemistry, usually colothe role of ECM on PAI-1 gene regulation. One can calizing with fibrin deposits and suggesting that fibrinspeculate that alterations in either the amount or the trapped PAI-1 may inhibit local plasminogen activation composition of ECM may alter the PAI-1 synthesis and and thus prevent fibrinolysis (Fig. 3) . Glomerular cells, accumulation in the surrounding matrix. This may apply mainly endothelial and mesangial cells, and vascular to mesangial cells but also to any other renal parenchycells, were shown to express PAI-1 by in situ hybridizamal cells. tion (Fig. 3) of fibrin in the lungs of experimental animals and to prethis study the late fibrotic phase of the disease was not studied. It has also been shown that in the anti-Thy 1.1 vent most of the pulmonary fibrosis. Conversely, overexpression of PAI-1 in transgenic mice increased both glomerulonephritis in the rat, glomerular matrix accumulation is linked to inhibition of the plasminogen system fibrin accumulation and the severity of the subsequent fibrosis. In our opinion, the best scenario that can be by PAI-1 [54] . A recent study indicates that PAI-1 may be involved in the pathogenesis of glomerular and vascuproposed is that PAI-1 accumulation at sites of fibrin formation inhibits fibrinolysis and MMP activation. The lar sclerosis after irradiation [31] . In this model, a strong activation of the renin-angiotensin system has been demfibrin matrix has been shown to be progressively invaded by fibroblasts, which produce large amounts of collagens, onstrated as well as a strong induction of PAI-1 synthesis in the kidney. The inhibition of angiotensin I-converting and make the fibrin matrix more resistant to digestion. Local inhibition of MMP activation may also explain enzyme (ACE) by enalapril or of angiotensin II (Ang II) receptors by losartan prevented PAI-1 up-regulation and the progressive accumulation of ECM proteins and the development of fibrosis (Fig. 5) .
the late development of renal fibrosis and renal failure. These results also suggest that Ang II stimulates PAI-1 To date, similar proofs for PAI-1 involvement in renal fibrosis are lacking. Indirect evidence for a role of PAI-1 synthesis in vivo, which in turn inhibits ECM degradation and promotes renal fibrosis. In vitro experiments have was provided when Kitching et al demonstrated that plasminogen and plasminogen activators protect against renal shown that Ang II increases PAI-1 synthesis by mesangial cells [54] . However, in some cell types such as endoinjury in crescentic glomerulonephritis [53] . However, in inhibits further plasmin generation and thus TGF-␤ activation. The plasmin-TGF-␤ interaction could therefore angiotensin IV but not Ang II activates PAI-1 synthesis. This effect seems mediated by specific angiotensin IV appear as an autolimited process that will allow transient and timely regulated degradation and synthesis of ECM receptors different from angiotensin II type 1 or 2 (AT1 or AT2) receptors. In addition, the short-term effects of proteins. Interestingly, in this potential scenario, PAI-1 would be required to prevent prolonged TGF-␤ activaAng II on matrix protein synthesis and on PAI-1 are prolonged by a long-term effect of TGF-␤, in which the tion and further development of fibrosis. However, TGF-␤ is considered to be a major fibrogenic molecule, at least synthesis is also induced by Ang II [57, 58] . More recently, a reduced angiotensinogen expression has been shown in many experimental [61, 62] and human kidney diseases, such as chronic glomerulonephritis [37], diabetic neto attenuate renal interstitial fibrosis in obstructive nephropathy in mice [59] . In this study, the Ang II-mediphropathy [36], focal segmental glomerulosclerosis [37], HIV-associated nephropathy, and chronic allograft neated TGF-␤ expression seemed involved in the renal fibrogenic process independently of the systemic blood phropathy and the associated interstitial fibrosis [63] . The effects of TGF-␤ on ECM protein synthesis and on pressure.
Transforming growth factor-␤ is a potent inducer of inhibitors of ECM degradation in the kidney may overcome the stimulating effect on MMP synthesis. Among PAI-1 synthesis through the activation of Smad3 and Smad4, two transcription factors that have been shown the inhibitors, PAI-1 plays a central role as a component of the ECM and as an inhibitor of plasminogen activation recently to mediate almost all, if not all, of the effects of TGF-␤ on PAI-1 gene transcription [23] . TGF-␤ is [64] . It has recently been shown that the interstitial fibrosis associated with protein-overload proteinuria was also a potent cytokine stimulating collagen IV, fibronectin, and laminin production in the kidney [60] . In addiless pronounced in PAI-1-deficient mice than in their wild-type controls, further supporting a role for PAI-1 in tion, it increases the synthesis of MMP2 and MMP9 and of TIMP-1 and TIMP-2, at least in vitro. The resulting renal fibrogenesis (abstract; Oda et al, J Am Soc Nephrol 10:578A, 1999). effect on ECM turnover and accumulation is hardly predictable from the analysis of such elementary effects. In
Transforming growth factor-␤ has been shown to be involved in the pathogenesis of diabetic glomeruloscleroaddition, it has been demonstrated in vitro that the latent form of TGF-␤ is secreted and binds to the ECM. Plassis [36] . Both TGF-␤ and PAI-1 have been demonstrated by immunohistochemistry on renal biopsy of diabetic min, and to a lesser extent u-PA, is able to cleave and promote the release of active TGF-␤ from this latent patients. In vitro, high-glucose medium increases the synthesis of TGF-␤ through the glucosamine 6-phosphate form. In turn, TGF-␤ stimulates ECM proteins synthesis and, at the same time, increases PAI-1 production, which pathway and the production of ECM proteins and of PAI-1 by cultured mesangial cells [65] . Furthermore, tered in these cases, which seem to favor thrombosis and extension of myocardial ischemia. Obviously, this is a when cultured on nonenzymatically glycated collagen I, endothelial cells have been shown to up-regulate their short-term treatment that is associated with a risk of immunization against heterologous antibodies and a prosynthesis of PAI-1.
The PAI-1 4G/5G polymorphism, which correlates gressive lost of efficacy. In addition, it requires intravenous injection and would not be easy to administer. Rewith the PAI-1 plasma level, has been investigated in diabetic patients. Controversial results were reported nal diseases that may need such PAI-1 inhibition have a prolonged course and would require a long-term blocksince in Japanese patients with type II diabetes, the 4G/4G genotype was associated with more frequent vasade of PAI-1 action. A synthetic inhibitor of PAI-1 has been produced, cular complications than the 5G/4G or the 5G/5G genotypes, but the incidence of diabetic nephropathy was the derived from the reactive center loop of PAI-1 and which induces the inactive conformation of PAI-1 [68]. This 14 same in the three groups [66] . Similarly, in Caucasian patients with type I diabetes, the 4G/4G genotype was amino acid residue inhibitor has been shown to rapidly inhibit PAI-1 function and the formation of t-PA/PAI-1 significantly associated with diabetic retinopathy but not with diabetic nephropathy (abstract; Pucci et al, J Am complexes in vitro. This peptide has a poor inhibitory effect of vitronectin-bound PAI-1, but is able to enhance Soc Nephrol 10:132, 1999). In contrast, in Chinese patients with type II diabetes, the 4G/4G genotype was sigin vitro lysis of platelet-rich clots and platelet-poor clots containing recombinant PAI-1. Clearly, this approach nificantly associated with diabetic nephropathy, and this effect was even more pronounced in patients with the DD may be used to increase the intravascular fibrinolytic activity in vivo, while the tissue vitronectin-bound PAI-1 genotype for ACE [67] . Further large scale studies are required to determine the role of PAI-1 in human diabetic remains fully active. Experimental studies of thrombotic microangiopathy, as recently described after endotoxin nephropathy. To our knowledge, no study has reported on experimental diabetic nephropathy in PAI-1-deficient and ricin administration in the rat [69] , are required to evaluate the effect of such a circulating PAI-1 inhibitor, or PAI-1-overexpressing mice, but this experimental apgiven either before disease induction or later, when miproach is worth testing.
crothrombosis is already present. In the future, the design of other PAI-1 inhibitors would be useful if these MODULATION OF PAI-1 SYNTHESIS OR compounds can be administered per os on a long-term OF PAI-1 ACTIVITY AS FUTURE basis.
THERAPEUTIC INTERVENTIONS
The blockade of PAI-1 synthesis in vivo has not been From animal studies using genetically modified mice reported but is theoretically a potential way of treatment. overexpressing or deficient in u-PA, t-PA, plasminogen, Specific inhibition of PAI-1 gene expression may be or PAI-1, it has been possible to evaluate the physiologiachieved using the antisense oligonucleotide strategy cal role of each of these molecules [6] . The isolated deficit [70, 71] . This strategy has been shown to block PAI-1 in t-PA, u-PA, or PAI-1 is not associated with an obvious synthesis efficiently in cultured cells in vitro. However, abnormal phenotype, but there is a tendency to thrombono report is available concerning the in vivo efficacy of sis for t-PA and u-PA and to bleeding for PAI-1 deficit.
these oligonucleotides. Transfection of renal cells in vivo In contrast, mice deficient in plasminogen or in both t-PA has been reported but remains difficult and requires apand u-PA exhibit a reduced growth rate, a tendency to propriate vectors. Similarly, PAI-1 synthesis could be thrombosis, and a delay in wound healing. PAI-1-deficient inhibited by decoy oligonucleotides directed to the one mice are protected from thrombosis and fibrosis after or two main transcription factors, which are activated in fibrinous alveolitis [51] . Transgenic mice overexpressing diseased conditions and which increase PAI-1 gene tran-PAI-1 have been reported to be prone to thrombosis scription. These transcription factors may very likely vary and tissue fibrin deposition and to late development of according to the underlying renal diseases. For example, fibrosis. It has been suggested that PAI-1 inhibition transcription factors activated by thrombin such as AP-1, would thus be beneficial for the prevention of thrombosis NF-B, and thrombin-induced nuclear factor (TINF) and of fibrin-derived fibrosis.
may be adequate targets of decoy oligonucleotides when Different methods of inhibition are available: neucoagulation and fibrin formation play an important role tralizing anti-PAI-1 antibodies, synthetic antagonists of in the pathogenesis of the renal diseases, that is throm-PAI-1, and inhibitors of PAI-1 synthesis. These apbotic microangiopathy and extracapillary glomeruloneproaches are still experimental, but could be useful in phritis. On the other hand, Smad3 and Smad4 would be evaluating the therapeutic effect of PAI-1 inhibition in the potential targets of decoy oligonucleotides to prevent vivo. Anti-PAI-1 antibodies have been proposed to pre-TGF-␤-mediated renal PAI-1 synthesis and fibrosis in vent rethrombosis shortly after myocardial infarction, hypertensive, diabetic, or autoimmune nephropathies [23] . This strategy would block most of the effects of since high plasma levels of PAI-1 are frequently encoun-the TGF-␤ pathway and may be efficient to lessen the diseases, especially in vascular remodeling after intimal severity of renal diseases, since inhibition of TGF-␤1 injury or in chronic transplant arteriopathy. Transgenic expression by antisense oligonucleotides has been shown mice deficient in PAI-1 or overexpressing it are potent to suppress ECM accumulation in experimental glomertools to dissect the respective contribution of PAI-1 in ulonephritis induced by anti-Thy 1.1 antibody [72] .
the different models of renal fibrogenesis. Several ways Although the inhibition of PAI-1 synthesis or activity of PAI-1 inhibition are proposed but need to be evalumay prove useful in fibrogenic renal injuries, it has to ated in the various forms of renal diseases. be emphasized that PAI-1 may also have a protective intimal injury in mice, it has been shown that u-PA defi-E-mail: rondeau@b3e.jussieu.fr ciency delays re-endothelialization of the vessel but that PAI-1 deficiency is associated with an increased intimal REFERENCES hyperplasia when compared with wild-type controls. 
